Topical Lipophilic Epigallocatechin-3-gallate on Herpes Labialis: a Phase II Clinical Trial of AverTeaX Formula.
Man Zhao,Rong Zheng,Jinyan Jiang,Douglas Dickinson,Baiping Fu,Tin-Chun Chu,Lee Hwang Lee,Henna Pearl,Stephen Hsu
DOI: https://doi.org/10.1016/j.oooo.2015.08.018
2015-01-01
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Abstract:OBJECTIVE:Previous in vitro and in vivo studies indicated that catechins from the tea plant (Camellia sinensis) have a therapeutic effect on herpes simplex virus infections. The aim of this study was to clinically evaluate a topical proprietary formulation containing lipophilic catechins (AverTeaX, Camellix, LLC, Evans, GA, USA) on recurrent herpes labialis.STUDY DESIGN:A double-blind, placebo-controlled, randomized trial with 40 participants, initially in two groups.RESULTS:Compared with the vehicle (100% glycerin USP, CVS Pharmacies, Inc., Woonsocket, RI, USA) group, AverTeaX applied topically six to eight times daily resulted in a significant reduction in clinical episode duration (median 4.5 days vs. 9 days; P = .003) and shortened blistering and ulceration stages within an episode from a median of 3 days to 1 day (P = .0003). Median quality-of-life scores, based on a multiquestion survey, showed significant differences between the groups with respect to duration of itching, from a median of 4 days to 1 day (P = .0021), and duration until symptom free, from a median of 8 days to 4 days (P = .0016). Significant differences were not found for median scores for itching, pain, burning, swelling, bleeding, and stress. Adverse effects were not reported.CONCLUSION:AverTeaX formulation containing lipophilic catechins effectively inhibited herpes simplex labialis infection with clinical significance.